Navigation Links
PharmAthene Reports First Quarter 2008 Financial Results
Date:5/13/2008

ommence the first Phase I safety study in humans, which is expected to

be completed early next year.

Financial Results

PharmAthene received revenues of $5.8 million for the three months ended March 31, 2008 compared to $3.0 million for the same period in 2007. These revenues consist primarily of contract and grant funding from the U.S. government for the development of the Company's chemical nerve agent prophylaxis, Protexia(R).

PharmAthene's research and development expenses were $5.9 million and $3.1 million for the three months ended March 31, 2008 and 2007, respectively. These expenses resulted primarily from research and development activities related to the development of Valortim(TM) for protection against and treatment of inhalation anthrax, and the development of Protexia(R) for treatment of nerve agent poisoning. Research and development expense increased $2.8 million for the three months ended March 31, 2008 as compared to the same period in 2007, primarily as a result of increased process development and manufacturing activities for both Valortim(TM) and Protexia(R), and employee-related expenses including stock compensation expense.

General and administrative expenses for the Company were $4.7 million and $2.5 million respectively, for the three months ended March 31, 2008 and 2007. Expenses associated with general and administrative functions for the Company increased $2.2 million primarily due to increased employee costs, increased stock compensation expense and additional costs associated with the Company's compliance and legal functions.

PharmAthene's net loss for the first quarter of 2008 was $5.0 million or $0.23 per share.

As of March 31, 2008, available cash, cash equivalents and short term investments were $25.7 million, after giving effect to $20.0 million in restricted cash.

Conference Call Information

PharmAthene management will host a conference call to discuss the Company's f
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
2. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
3. PharmAthene Reports Year-End 2007 Financial Results
4. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
5. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
6. PharmAthene to Delay Release of Full Year 2007 Financial Results
7. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
10. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
11. PharmAthene to Present at the BIO CEO & Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... FOSTER CITY, Calif. , April 20, 2015 /PRNewswire/ ... with InterpretOmics Pvt. Ltd. to provide an integrated Big ... analysis of all biomarkers collected in the context of ... the needs of precise or multi-targeted drug candidates, stratified ... efficacy and disease progression free survival. ...
(Date:4/20/2015)... 2015  "Everybody is affected by cancer sooner or ... frankly brutal. We,ve got to get away from that."  ... witnessed a loved one or friend battling for their ... chemotherapy and other treatments cause the human body. It,s ... up and succumb to the disease. Dr. Dionne has ...
(Date:4/20/2015)... /CNW/ - Portage Biotech Inc. ("Portage" or "the Company") ... to announce that its wholly owned subsidiary, Portage Pharmaceuticals ... showed one of its proprietary human-derived CPP sequences and ... inhibition of NFkB signalling even if administered when the ... the blood brain barrier (BBB) in mice was studied ...
(Date:4/20/2015)... 2015   Meditope Biosciences, Inc ., a biotechnology ... today announced presentation of data demonstrating the use of ... conjugates (ADCs). The data were presented in an abstract at ... in Philadelphia . ... to the many commercial applications that may be possible ...
Breaking Biology Technology:PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2
... Arpida Ltd,(SIX: ARPN) announced today its financial results for the year ending 31,December ... - Setback in regulatory process for intravenous iclaprim in US, ... - Top-line results of "intravenous-to-oral" Phase II trial with oral, ... change, - Share placing, Cash ...
... Feb. 25 Cerimon Pharmaceuticals, Inc., announced ... its once-daily topical diclofenac sodium patch Phase III program. ... Phase III clinical studies with Cerimon,s diclofenac patch. ... Cerimon,s diclofenac patch compared to placebo for the treatment ...
... SAN DIEGO and MONTREAL, Feb. 25 Speid ... consultancy firm today announced that it has entered ... success rates of new drug compounds using Genizon,s ... climate in which innovative pharmaceutical and biotechnology companies ...
Cached Biology Technology:Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds 2
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... leaves influence the sunlight reaching inner canopy leaves by changing ... physiology of leaves within the tree canopy is not constant, ... crown. This phenomenon is expected to have important consequences for ... A new study describes how the leaves in the outer ...
... cell in your body, but the ability to view them ... experimental techniques. A team of scientists working at the National ... Irvine, recently developed a way to magnify them dramatically. Their ... this boundary between the cell and the outside world. ...
... the United States and China have discovered the first ... flowering plant whose membership includes buttercups, apple trees, maple ... in this week,s Nature, reveals a remarkably developed species, ... of the eudicots -- and perhaps flowering plants in ...
Cached Biology News:Closer look at cell membrane shows cholesterol 'keeping order' 2Fossil is best look yet at an ancestor of buttercups 2Fossil is best look yet at an ancestor of buttercups 3
... a compact instrument for gene amplification (PCR). It ... 0.5 ml tubes, or a 48-well microplate. A ... adjust height and pressure to tightly seal PCR ... excellent thermal performance, and the sample block reaches ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
... Assay with SR-101 Labeled Substrates (red ... Accurately measure serine protease activation • ... B-Bridge's FLISP Kits utilize cell-permeable, fluorescently ... to measure chymotrypsin-like activity in whole ...
... is used in conjunction with your existing apoptosis ... apoptosis according to your existing procedure (also reserve ... control). Once you have induced apoptosis in your ... population and incubate the cells for an additional ...
Biology Products: